secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001062822-23-000055
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon Q3 net loss $50.5M ($0.21/sh); INPEFA revenue $0.4M since launch
------------------------------------------------------------------------

- Net loss of $50.5M vs $23.4M a year ago; loss per share $0.21 vs $0.13.
- Total Q3 revenue $0.2M; INPEFA net product revenues since June launch total $0.4M.
- Express Scripts placed INPEFA on Premier Access, Premier Performance (Medicare) and Basic/High Performance (commercial) formularies effective Nov 1.
- LX9211 Phase 2b enrollment expected to begin in December 2023 for diabetic peripheral neuropathic pain.
- Cash and investments $218.4M as of Sept 30, 2023, up from $138.4M at Dec 31, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282223000055/0001062822-23-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282223000055/lxrx-20231108.htm
  HTML page:      https://secwatch.observer/filing/0001062822-23-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer